Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.4800
+0.0300 (6.67%)
May 7, 2026, 3:59 PM HKT
Market Cap1.98B -2.0%
Revenue (ttm)718.98M +150.2%
Net Income63.58M
EPS0.01
Shares Out4.12B
PE Ratio43.13
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume232,000
Average Volume334,900
Open0.4550
Previous Close0.4500
Day's Range0.4550 - 0.5100
52-Week Range0.4000 - 0.8800
Beta0.61
RSI52.54
Earnings DateMay 28, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 383
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements